While studies representing a lower rate of these mutations mostly contain adenocarcinoma histological type, the higher numbers of MTAP and CDKN2A/B alteration incidences in our case could be due to squamous NSCLC patients, who accounted for 1/3 of all patients. The gene discussed is MTAP; the disease is non-small cell lung carcinoma.